DS 5141b

Drug Profile

DS 5141b

Alternative Names: DS-5141; DS-5141b

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Inc
  • Class
  • Mechanism of Action Dystrophin expression stimulants; Protein synthesis modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy

Most Recent Events

  • 25 Apr 2018 Topline safety and efficacy results from phase I/II trial in Duchenne muscular dystrophy released by Daichii Sankyo
  • 24 Apr 2017 The Ministry of Health, Labour and Welfare designates SAKIGAKE designation dystem to DS 5141b for Duchenne muscular dystrophy in Japan
  • 01 Oct 2015 Phase-I/II clinical trials in Duchenne muscular dystrophy in Japan (SC) (NCT02667483)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top